Ranbaxy Woes Continue With 33-Product Import Alert
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA restricts 26 finished drugs and seven API because of GMP violations.
You may also be interested in...
Why Baxter’s GMP False Claims Settlement Was Smaller Than Those Of GSK, Ranbaxy
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.
Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit
MUMBAI, India - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of company management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon
Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit
MUMBAI, India - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of company management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon